Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

February 26, 2026

MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:

- **TD Cowen 46th Annual Health Care Conference** – Dave Lennon, PhD, President and CEO, will participate in a hybrid presentation and fireside chat on Tuesday, March 3 at 10:30 AM ET
- **Leerink 2026 Global Healthcare Conference** – executives will participate in investor meetings on Monday, March 9
- **Citizens Life Sciences Conference** – Dave Lennon, PhD, President and CEO, will give a corporate presentation on Tuesday, March 10 at 12:30 PM ET

A live webcast of the TD Cowen and Citizens presentations can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302697787.html

SOURCE Whitehawk Therapeutics, Inc.